NCT07339852 Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies
| NCT ID | NCT07339852 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-10-13 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2025-10-13 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible. This research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18 years or older. 2. Individuals with type 2 diabetes. 3. Individuals with type 2 diabetes not reaching HbA1c target of under 7.0% Exclusion Criteria: 1. Individuals with type 1 diabetes, gestational diabetes, or other forms of diabetes that are not type 2 diabetes. 2. Pregnant individuals. 3. Individuals at their HbA1c target (HbA1c under 7.0%) or those with a limited life expectancy, frailty, or lack hypoglycemic awareness (i.e., those with an A1c target above 7.0%) . 4. Individuals unable to provide consent or who are unwilling to attend follow-up visits.
Contact & Investigator
Ross Tsuyuki, BScPharm, PharmD, MSc
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT07339852 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07339852 currently recruiting?
Yes, NCT07339852 is actively recruiting participants. Contact the research team at sgysel@ualberta.ca for enrollment information.
Where is the NCT07339852 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT07339852 clinical trial?
NCT07339852 is sponsored by University of Alberta. The principal investigator is Ross Tsuyuki, BScPharm, PharmD, MSc at University of Alberta. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.